Alphyn Biologics bags $25 million financing to advance breakthrough skin disease therapies
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
The new centre brings advanced corneal procedures pioneered in India
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
Roche says its new assay “resolves this challenge by delivering accurate and specific results
Akero became a wholly owned subsidiary of Novo Nordisk
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Subscribe To Our Newsletter & Stay Updated